Neutrogena-owner Kenvue's third-quarter sales fell short of expectations on Thursday, marking the fifth consecutive quarter of year-over-year decline in its core skin health and beauty products ...

In a report released today, Lauren Lieberman from Barclays maintained a Hold rating on Kenvue, Inc. (KVUE – Research Report), with a price ...

Barclays analyst Lauren Lieberman lowered the firm’s price target on Kenvue (KVUE) to $21 from $23 and keeps an Equal Weight rating on the ...

Public comments open before a final order is issued. Vandana Singh Listerine And Tylenol Maker Kenvue's Q3 Earnings: Revenue Miss On Weak Skin Health And Beauty Sales Kenvue reports Q3 sales of $3 ...

Kenvue Inc. closed $3.49 below its 52-week high ($24.46), which the company reached on November 26th.